Business
Microbix Announces Independent Evaluation Of Its Vaccine Yield Enhancement Technology
Microbix Announces Independent Evaluation Of Its Vaccine Yield Enhancement Technology.
About this update from Microbix Biosystems Inc.
[{"type":"text","content":"\n\n\n\n\nTORONTO, Dec. 6 /CNW/ - Microbix Biosystems Inc. (TSX:MBX) today\nannounced that an independent influenza research laboratory will be evaluating\nthe Company's proprietary technology for boosting influenza vaccine production\noutput.\nMicrobix is transferring its technology to the laboratory, located in a\nmajor North American teaching hospital, where the effectiveness of the process\nwill be tested and assessed. The final report is expected in about six months.\nMicrobix' technology has the potential to increase production yields of\ninfluenza vaccines significantly. This would be an important breakthrough in\ncombating a possible future flu pandemic, since annual global vaccine\nproduction capacity is currently only 300 million doses, far short of the\npotential pandemic requirement.\n\"We have every confidence in our technology,\" said William J. Gastle,\nPresident and CEO of Microbix. \"Numerous studies have already shown\nsignificant gains in viral yield. We look forward to this additional\nassessment as it will provide independent, objective guidance to the\nmanufacturers of influenza vaccines.\"\nThe Company reported its intention to seek an independent evaluation of\nthe technology in an earlier news release.\n\nMicrobix specializes in developing proprietary biological technologies\nand then commercializing those technologies through global partners. Its\nproducts include biotherapeutic drugs, vaccines, and infectious disease\ndiagnostics. Established in 1988, Microbix is headquartered in Toronto.\n\nThis press release contains forward-looking statements, which are subject\nto risks and uncertainties that could cause actual results to differ\nmaterially from those set forth in the forward-looking statements. For\ninstance, product development and field trials may proceed slowly or not at\nall and may not result in products that can be commercialized, savings by\nproducers may not reach value estimates or at all and sales may not reach\nsales targets or be made at all. These forward-looking statements represent\nthe Company's judgment as of the date of this press release. The Company\ndisclaims any intent or obligation to update these forward-looking statements.\n%SEDAR: 00004220E\n\n\n","length":2272,"tagName":"div"}]